How Can Big Data Simplify Pharmaceutical Data Management Processes? Big Data in Pharma

Dorota Owczarek - May 24, 2021

In the past few years, big data has emerged as a powerful tool for solving some of the most pressing scientific research and drug discovery challenges. One area where big data is making an impact is laboratory information systems and data management processes. The pharmaceutical industry relies heavily on big data and analytics to make better sense of the vast amounts of information about drugs, their interactions with our bodies, clinical research, and more. Imagine how much time will be saved if a researcher could easily find clinical trial records or other past work that might have involved similar patients? Currently, it can take days for researchers to comb through countless files to answer this question. But what happens when we apply predictive algorithms such as machine learning models? The problem is turned into an optimization problem which then provides new insights into solving issues related to pharmaceutical research. This article outlines some problems in data handling pharma currently faces before outlining opportunities afforded by advanced analytics techniques like machine learning that are helping solve these problems.

What is Big Data?

Big Data is a term that refers to the massive and varied datasets generated by recording digital touchpoints everywhere. Big data can come from website analytics, social media activity, customer feedback, manufacturing records, or anything else where computers are watching over our day-to-day lives. It’s often collected automatically using algorithms that monitor web usage for specific patterns (such as what people search for). This information is used to improve the content on websites, sell more products via targeted advertising and even predict disease outbreaks before they happen. For the life sciences industry, data sources are slightly different and include the following:

  • drug discovery research,
  • clinical research and clinical trials,
  • patients records and other health information,
  • manufacturing facilities/processes,
  • distribution data (POs, KSUs),
  • raw material records,
  • marketing and sales records from wholesalers, retailers, and distributors.

These data entries are combined and used to optimize drug discovery and development processes, clinical trials, drug manufacturing, and distribution through data analytics. Business intelligence tools and techniques need to be applied to make sense of the data, such as predictive analytics, sentiment analysis, text mining, or anomaly detection.

Lab Management Systems (LMS), another important data-heavy concept in the drug development and pharmacovigilance processes, can provide a single point of entry for laboratory requests for them to be processed by various laboratories within the organization or among different organizations who share resources. Supported by machine learning algorithms, they can bring new insights and new value.

The need for better data management in the pharma industry

The pharmaceutical industry is really complex, and this complexity has translated to the pharma needing better management of their data. For example, tracking drug distribution can be complicated because many different categories need to be captured (ex: Point-of-Sale Data from wholesalers, retailers, distributors). There’s also a lot of information in clinical trials and the drug development process, which needs to be sifted through for insights, such as identifying patterns across groups or looking at efficacy by delivery method. This complexity translates into pharma needing better data management to find pertinent insights from a vast amount of information. Other areas can benefit from using big data analytics as well, such as pharmaceutical supply chain with managing inventory levels, forecasting sales volumes, tracking patient need for drugs, and more.

Database pools in laboratories can be difficult to manage because they are separated from the main corporate database, and there is no correlation between them. This leads to various issues, including discrepancies, delays in reporting, missed opportunities for real-time actioning of observations, and waste due to duplication of workflows.

Clinical Data Management

Clinical Data Management (CDM) manages all clinical data and information, including raw datasets from clinical trials and coded patient medical records. CDMs manage this huge amount of data through coding methods designed for pharmaceutical industry standards such as HIPAA, ICH GCP guidelines, FDA regulations, etc. There is an increased need for clinical research transparency and better collaboration between all stakeholders to establish tighter drug safety regulations in the future. In addition, pharmacovigilance processes make it imperative to establish a solid clinical data management strategy.

The name Clinical Data Management is misleading because it implies that only clinical trials documents are involved when every type of document related to pharmaceutical research projects should have a place inside the system: case report forms, correspondence, financial records, regulatory affairs, or compliance reports.

Massive amounts of clinical trial data

The constantly growing, sheer amount of data generated by the life sciences companies has also made data management and interpretation a daunting task. For example, clinical trials often collect huge volumes of trial site reports on paper or via emails over time; these could be laboriously entered into databases days, weeks, or months after they were collected - by people who may not know how these pieces fit together in the bigger picture. This means it’s difficult to keep track of the clinical research data as a whole. The biggest challenge CDMs face in today’s drug discovery, and development environment is the constantly growing volume of clinical trial data generated by companies.

In addition to the high volume, the pharmaceutical CDM needs to manage diverse data entry types: structured and unstructured. Companies face nonstandardized parameters across different documents such as lab reports and electronic health records (EHRs) and lack of interoperability between various laboratory instruments leading to redundant operations/inaccurate results. The bulk of clinical trial documents are either PDFs or Excel files that are not normalized and have little structure (i.e., only title information), so retrieving needed content from these is a time-consuming process if performed manually because it involves scanning through countless pages/documents for relevant content while ignoring irrelevant ones.

Is the volume a problem only for big pharma companies?

No, it is not. Pharmaceutical industry data management faces a big challenge with the volume and variety of clinical trial documents in its pipeline. Big pharma organizations need more robust systems to manage this huge amount of data and provide an interface with end-users who can search and retrieve specific information without having to scan all available information sources themselves. For smaller organizations, data management problems are more narrow in scope, but the same algorithmic approaches can be applied to eliminate manual, time-consuming work.

How can Big Data help simplify data management processes?

Pharma is one of the most data-intensive industries globally, and big data promises to simplify laboratory information systems (LIS) and data management processes. Big Data is not just a buzzword but also an opportunity to eliminate manual processes and increase efficiency. With the wide availability of big data analytics tools in cloud-based infrastructures like Amazon Web Services (AWS), it became easier for pharmaceutical companies to build robust systems that meet their needs. Pharma organizations can offer their employees easy access to clinical trial documents through customized dashboards or by providing them with self-service portals to search and retrieve specific information without scanning all available sources themselves. As smaller organizations have more narrow data management issues, big data approaches can be applied as well - especially when it comes down to time-consuming activities such as document scanning or reporting from contract research organizations ( CROs).

CDM is an important part of the pharma supply chain operations. It holds information on clinical trials, clinical research, patient profiles that have been collected through the company’s marketing efforts, or health care providers that collaborate with them. The biggest pharma organizations invest heavily in CDM initiatives using tools like Hadoop-based platforms, cloud services, advanced analytic techniques (e.g., predictive modeling), machine learning algorithms, etc.

Big Data and analytics can help by providing insights on potential distribution channels or markets where pharmaceuticals could be sold more effectively; they can facilitate inventory control systems that integrate suppliers’ information about raw materials availability; they can provide faster responses to adverse events through real-time alerts from wholesalers/distributors supplying patients outside the company’s scope.

In addition, big data and analytics can help in the creation of “CDS.” CDS is a highly customizable clinical decision support system that integrates drug-specific information on safety, efficacy, pharmacokinetics (PK)/pharmacodynamics (PD), and other vital parameters to provide clinicians with specific recommendations for each individual patient or per specific medication.

In conclusion, big data analytics provides pharmaceutical companies with opportunities to improve their efficiency by eliminating the need for manual entry of information and providing actionable insights. In other words, drug safety could be improved through better monitoring systems; clinical studies can be done more efficiently because they are driven by evidence-based decision support tools rather than gut instincts or a “best guess” approach; inventory control is also improved from real-time alerts about availability of raw materials.

What challenges could arise from implementing Big Data into pharmaceutical companies?

The potential cost of implementation

The biggest challenge that pharmaceutical companies will face when implementing machine learning systems is the potential cost of implementation. It can be not easy to decide which data sources are relevant and how much investment should go towards this development initiative. Additionally, there needs to be a data governance plan in place so that all parties involved have access to the same information at any given time for it to have true value.

Poor quality data leads to poor outcomes

Poor quality data from a pharmaceutical company’s database can lead to having poor outcomes when implementing artificial intelligence solutions. It might occur that the data will need to be cleaned up before it can truly be leveraged for meaningful insights. There is a significant cost associated with this clean-up process, which can be difficult to justify when the data does not have an immediate use.

The cost of big data storage

Another potential challenge would be the cost of storing all the datasets collected by biopharma companies over time, especially if they want to store them forever. These costs can quickly add up without any clear ROI on how big data could help improve their business operations even more than it already does?

Lack of expertise within the company

Not every pharma company has Data Scientists on board. With a lack of expertise and knowledge, it can be difficult to implement big data strategies that drive value. You’ll need experts trained in statistical programming skills for deep learning algorithms and business intelligence skills for data exploration and visualization and emphasize collaboration to innovate.

The challenge of making sense of pharma datasets

On top of the lack of expertise, there is also difficulty understanding all the different types of pharmaceutical data that need to be captured, analyzed, and managed. There are many unstructured forms such as PDFs or scanned documents that can’t easily be parsed with traditional tools. Engineers working on the problem should work closely with pharma business experts for the best results.

Innovation can be scary.

The next big hurdle would probably be training employees on new processes or using different tools - even though these challenges could also provide opportunities for innovation within an organization. There is little incentive for stakeholders to change their behavior until they see tangible benefits from big data adoption. This will require better communication around what problems data analytics solutions solve, so it’s easier to convince them to adopt new practices over old ones. The most significant obstacle preventing this transition seems to be one rooted in changing human behavior, not technology obstacles.

Questions to Ask Yourself Before Integrating Big Data into Your Data Management Operations

You should ask yourself and your co-workers several questions to identify if big data is right for you.

  • Do I have a business problem that needs to be solved?
  • What do we want to achieve with big data, specifically regarding my company’s business goals?
  • Can my company afford the upfront costs of implementing and managing big data solutions?
  • How much time am I willing to invest in learning about big data, understanding how it works, and evaluating its potential benefits?
  • Who will be responsible for developing a strategy for how this data should be used internally at my organization?
  • What cultural barriers within your organization will require significant change before beginning integration with big data?
  • Is there an organizational change that needs to happen before integrating big data into the organization’s processes or operations?
  • Where do I stand on making changes versus sticking with what has been tried and tested over decades of practice within your industry or sector?

Once you answer these questions, there should be no question whether integrating big data analytics into your current practices is worth exploring further. If so: proceed!

How to successfully implement AI-powered Data Processing at your company

To decrease the possibility of failure, think about approaching the implementation in an iterative way that embraces the culture of experimentation. Choose a strategic partner or solution provider whose experience will help you reach your goals.

Start small with AI Design Sprint to get aligned on the core problem, business goals, and possible solutions. Next, move on to the Proof of Concept phase to validate the solution and dig deeper into the data and processes you already have. The next steps are to determine the costs, risks, and timeline for your production-ready project and move on with the implementation of a scalable solution. Build automated pipelines, scale, and deploy your artificial intelligence app into production.

Summary

The artificial intelligence revolution has already begun in pharmaceuticals, and it will only continue to grow as more companies begin to harness its power. The potential for what can be achieved is virtually limitless. Still, there are steps that need to take place first: defining goals, choosing solutions partners, understanding current processes, refining use cases, and understanding the technological capabilities before implementing an AI-powered workflow.

If you need help with big data in the pharmaceutical industry, contact us today for more information about the process and to see how we can assist!

References

How data is changing the pharma operations world - McKinsey

About the author

Dorota Owczarek

AI Product Lead & Design Thinking Facilitator

With over ten years of professional experience in designing and developing software, Dorota is quick to recognize the best ways to serve users and stakeholders by shaping strategies and ensuring their execution by working closely with engineering and design teams. She acts as a Product Leader, covering the ongoing AI agile development processes and operationalizing AI throughout the business.

This article is a part of

7 / 10 articles

AI in Pharma

The pharmaceutical industry is one of the most regulated industries in the world. It's also one of the most expensive and challenging industries to work in. Pharma companies, like all other businesses, are looking for ways to reduce costs while improving quality and efficiency. This is where artificial intelligence comes into play!

Follow our article series to find out what are the benefits of AI in pharma and why this tech could be considered a game changer for the pharmaceutical sector.

check it out

More articles

Find us on

Need help with implementing AI in your business?

Let's talk blue circle

This site uses cookies for analytical purposes.

Accept Privacy Policy

In the interests of your safety and to implement the principle of lawful, reliable and transparent processing of your personal data when using our services, we developed this document called the Privacy Policy. This document regulates the processing and protection of Users’ personal data in connection with their use of the Website and has been prepared by Nexocode.

To ensure the protection of Users' personal data, Nexocode applies appropriate organizational and technical solutions to prevent privacy breaches. Nexocode implements measures to ensure security at the level which ensures compliance with applicable Polish and European laws such as:

  1. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation) (published in the Official Journal of the European Union L 119, p 1); Act of 10 May 2018 on personal data protection (published in the Journal of Laws of 2018, item 1000);
  2. Act of 18 July 2002 on providing services by electronic means;
  3. Telecommunications Law of 16 July 2004.

The Website is secured by the SSL protocol, which provides secure data transmission on the Internet.

1. Definitions

  1. User – a person that uses the Website, i.e. a natural person with full legal capacity, a legal person, or an organizational unit which is not a legal person to which specific provisions grant legal capacity.
  2. Nexocode – NEXOCODE sp. z o.o. with its registered office in Kraków, ul. Generała Henryka Kamieńskiego 51, 30-644 Kraków, entered into the Register of Entrepreneurs of the National Court Register kept by the District Court for Kraków-Śródmieście in Kraków, 11th Commercial Department of the National Court Register, under the KRS number: 0000686992, NIP: 6762533324.
  3. Website – website run by Nexocode, at the URL: nexocode.com whose content is available to authorized persons.
  4. Cookies – small files saved by the server on the User's computer, which the server can read when when the website is accessed from the computer.
  5. SSL protocol – a special standard for transmitting data on the Internet which unlike ordinary methods of data transmission encrypts data transmission.
  6. System log – the information that the User's computer transmits to the server which may contain various data (e.g. the user’s IP number), allowing to determine the approximate location where the connection came from.
  7. IP address – individual number which is usually assigned to every computer connected to the Internet. The IP number can be permanently associated with the computer (static) or assigned to a given connection (dynamic).
  8. GDPR – Regulation 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of individuals regarding the processing of personal data and onthe free transmission of such data, repealing Directive 95/46 / EC (General Data Protection Regulation).
  9. Personal data – information about an identified or identifiable natural person ("data subject"). An identifiable natural person is a person who can be directly or indirectly identified, in particular on the basis of identifiers such as name, identification number, location data, online identifiers or one or more specific factors determining the physical, physiological, genetic, mental, economic, cultural or social identity of a natural person.
  10. Processing – any operations performed on personal data, such as collecting, recording, storing, developing, modifying, sharing, and deleting, especially when performed in IT systems.

2. Cookies

The Website is secured by the SSL protocol, which provides secure data transmission on the Internet. The Website, in accordance with art. 173 of the Telecommunications Act of 16 July 2004 of the Republic of Poland, uses Cookies, i.e. data, in particular text files, stored on the User's end device.
Cookies are used to:

  1. improve user experience and facilitate navigation on the site;
  2. help to identify returning Users who access the website using the device on which Cookies were saved;
  3. creating statistics which help to understand how the Users use websites, which allows to improve their structure and content;
  4. adjusting the content of the Website pages to specific User’s preferences and optimizing the websites website experience to the each User's individual needs.

Cookies usually contain the name of the website from which they originate, their storage time on the end device and a unique number. On our Website, we use the following types of Cookies:

  • "Session" – cookie files stored on the User's end device until the Uses logs out, leaves the website or turns off the web browser;
  • "Persistent" – cookie files stored on the User's end device for the time specified in the Cookie file parameters or until they are deleted by the User;
  • "Performance" – cookies used specifically for gathering data on how visitors use a website to measure the performance of a website;
  • "Strictly necessary" – essential for browsing the website and using its features, such as accessing secure areas of the site;
  • "Functional" – cookies enabling remembering the settings selected by the User and personalizing the User interface;
  • "First-party" – cookies stored by the Website;
  • "Third-party" – cookies derived from a website other than the Website;
  • "Facebook cookies" – You should read Facebook cookies policy: https://www.facebook.com/policy/cookies
  • "Other Google cookies" – Refer to Google cookie policy: www.google.com/policies/technologies/types/

3. How System Logs work on the Website

User's activity on the Website, including the User’s Personal Data, is recorded in System Logs. The information collected in the Logs is processed primarily for purposes related to the provision of services, i.e. for the purposes of:

  • analytics – to improve the quality of services provided by us as part of the Website and adapt its functionalities to the needs of the Users. The legal basis for processing in this case is the legitimate interest of Nexocode consisting in analyzing Users' activities and their preferences;
  • fraud detection, identification and countering threats to stability and correct operation of the Website.

4. Cookie mechanism on the Website

Our site uses basic cookies that facilitate the use of its resources. Cookies contain useful information and are stored on the User's computer – our server can read them when connecting to this computer again. Most web browsers allow cookies to be stored on the User's end device by default. Each User can change their Cookie settings in the web browser settings menu: Google ChromeOpen the menu (click the three-dot icon in the upper right corner), Settings > Advanced. In the "Privacy and security" section, click the Content Settings button. In the "Cookies and site date" section you can change the following Cookie settings:

  • Deleting cookies,
  • Blocking cookies by default,
  • Default permission for cookies,
  • Saving Cookies and website data by default and clearing them when the browser is closed,
  • Specifying exceptions for Cookies for specific websites or domains

Internet Explorer 6.0 and 7.0
From the browser menu (upper right corner): Tools > Internet Options > Privacy, click the Sites button. Use the slider to set the desired level, confirm the change with the OK button.

Mozilla Firefox
browser menu: Tools > Options > Privacy and security. Activate the “Custom” field. From there, you can check a relevant field to decide whether or not to accept cookies.

Opera
Open the browser’s settings menu: Go to the Advanced section > Site Settings > Cookies and site data. From there, adjust the setting: Allow sites to save and read cookie data

Safari
In the Safari drop-down menu, select Preferences and click the Security icon.From there, select the desired security level in the "Accept cookies" area.

Disabling Cookies in your browser does not deprive you of access to the resources of the Website. Web browsers, by default, allow storing Cookies on the User's end device. Website Users can freely adjust cookie settings. The web browser allows you to delete cookies. It is also possible to automatically block cookies. Detailed information on this subject is provided in the help or documentation of the specific web browser used by the User. The User can decide not to receive Cookies by changing browser settings. However, disabling Cookies necessary for authentication, security or remembering User preferences may impact user experience, or even make the Website unusable.

5. Additional information

External links may be placed on the Website enabling Users to directly reach other website. Also, while using the Website, cookies may also be placed on the User’s device from other entities, in particular from third parties such as Google, in order to enable the use the functionalities of the Website integrated with these third parties. Each of such providers sets out the rules for the use of cookies in their privacy policy, so for security reasons we recommend that you read the privacy policy document before using these pages. We reserve the right to change this privacy policy at any time by publishing an updated version on our Website. After making the change, the privacy policy will be published on the page with a new date. For more information on the conditions of providing services, in particular the rules of using the Website, contracting, as well as the conditions of accessing content and using the Website, please refer to the the Website’s Terms and Conditions.

Nexocode Team